Comerica Bank
BCAX

Comerica Bank’s Bicara Therapeutics BCAX Stock Holding History

Comerica Bank’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$202 Buy
+12
New +$205 ﹤0.01% 3671

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Comerica Bank's BCAX Position: Q4 2025 in Review

Comerica Bank opened a new position in Bicara Therapeutics (BCAX) in Q4 2025: 12 shares worth $202. The stake represents ﹤0.01% of the portfolio and ranks #3671 among its holdings.

141 funds tracked by Wall St. Rank hold BCAX as of Q4 2025.

  • Comerica Bank held 12 shares of Bicara Therapeutics worth $202 as of Q4 2025.
  • Bicara Therapeutics was a new Comerica Bank position in Q4 2025.
  • Bicara Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3671 holding.
  • 141 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.